- In August 2026, a Delaware jury found that a Qiagen subsidiary willfully infringed three patents exclusively licensed by 10x Genomics, awarding the company over US$4.8 million in damages based on a 14% royalty rate on Evercode Whole Transcriptome sales from February 2021 to June 30, 2026.
- The verdict strengthens 10x Genomics’ intellectual property position as it seeks a permanent U.S. injunction and additional damages, potentially influencing competitive dynamics in single-cell and spatial biology tools.
- We’ll now examine how this patent infringement win, and 10x Genomics’ push for an injunction, may reshape its broader investment narrative.
We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
10x Genomics Investment Narrative Recap
To own 10x Genomics, you need to believe its single cell and spatial platforms can become indispensable lab infrastructure, even as funding and pricing pressure weigh on growth and profitability. The Qiagen verdict reinforces 10x’s IP moat and may support its push for a U.S. injunction, but the most important near term catalyst remains uptake of newer, lower cost consumables, while the biggest risk is still persistent losses and sensitivity to constrained research budgets.
Among recent announcements, the April 2026 launch of Atera, a whole transcriptome spatial platform with single cell sensitivity, is most relevant here. Stronger IP protection from the Qiagen case could matter more as Atera enters a competitive market, potentially shaping how rivals position their own spatial tools and how customers weigh platform longevity and legal risk when committing scarce capital.
Yet beneath the patent win, investors should also be aware that continued operating losses and funding headwinds could still...
Read the full narrative on 10x Genomics (it's free!)
10x Genomics' narrative projects $781.5 million revenue and $128.8 million earnings by 2029. This requires 8.2% yearly revenue growth and a $203.9 million earnings increase from -$75.1 million today.
Uncover how 10x Genomics' forecasts yield a $49.54 fair value, a 21% downside to its current price.
Exploring Other Perspectives
More bullish analysts were already assuming revenue could reach about US$828 million by 2029, so if you see IP wins tightening competition and amplifying consumables growth, you may lean closer to that optimistic view, while still recognizing that others focus more on funding risk and volatile instrument demand.
Explore 4 other fair value estimates on 10x Genomics - why the stock might be worth as much as $50.00!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your 10x Genomics research is our analysis highlighting 1 key reward and 3 important warning signs that could impact your investment decision.
- Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.
Contemplating Other Strategies?
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
- Invest in the nuclear renaissance through our list of 92 elite nuclear energy infrastructure plays powering the global AI revolution.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 19 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com